July 26, 2019 07:17 AM EDT
R&D
FDA+

Nek­tar takes a hit as the FDA swerves away from opi­oid re­views — leav­ing NK­TR-181 in lim­bo

John Carroll

Editor & Founder

Nek­tar Ther­a­peu­tics took an­oth­er hit on Thurs­day af­ter the biotech re­port­ed that its opi­oid pain drug NK­TR-181 was be­ing put on hold at the FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times